Science Daily

2008-12-17T23:46:00.002-08:00

Science Daily is a free online news source. It features news and articles on a variety of topics including: computer science, nanotechnology, medicine, psychology, biology, climate, space, physics, mathematics, chemistry, archeology, paleontology, and others.

It has been active since 1995. The articles are selected from news releases submitted by universities and other research institutions. Some have criticized the site's refusal to provide links to the specific release on which each article is based, and its decision to list instead the home page of the institution responsible for the release--a practice that makes it difficult for researchers and interested laymen to cite and consult the actual scientific paper discussed.

Science Daily

2008-12-17T23:46:00.001-08:00

Man's Health

2008-12-17T23:43:00.000-08:00

The hormonal side-effects experienced by the three treatment groups were similar to previously reported effects for androgen deprivation hormone therapy.

Patients receiving degarelix were much more likely to experience injection-site reactions than those receiving leuprolide (40 per cent compared to one per cent).

However degarelix patients suffered fewer urinary tract infections than those in the leuprolide group (three per cent versus nine per cent) together with fewer joint pains and chills (four per cent versus nine per cent).

“More than 2,000 patients have now taken part in clinical trials for degarelix and there have been no signs of immediate or late-onset systemic allergic reactions, in contrast to other reported trials of other GnRH antagonists” points out Dr Klotz.

“The aim of the study was to show that degarelix was not inferior to leuprolide when it came to maintaining low testosterone levels over a one-year treatment period. We have conclusively shown that this is the case.

“However, we have also demonstrated that degarelix - which is an antagonist - offers an advantage, in that it reduces testosterone and PSA levels very quickly. It doesn’t cause the initial surge of testosterone seen with agonist drugs like leuprolide - the other drug featured in this study.

“This is relevant as biochemical surges in testosterone can stimulate the prostate cancer cells and cause unpleasant side effects for patients. They may also require further drug therapy to counteract the effects of agonist drugs like leuprolide.”